The efficacy of ICI in KRAS mutant non-squamous NSCLC in the beyond first-line setting was also investigated in patients who received nivolumab in an Italian expanded access program (EAP) study (82). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.